drugset / Trial / NCT01067859

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

NCT01067859 ↗

Phase 2 Terminated 5 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.

Timeline

Start
2010-03
Primary completion
2010-09
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cinaciguat Small molecule 10 ug Intravenous
Subject Cinaciguat Small molecule 25 ug Intravenous

Indications